GPR139 GPCR agonist

oral (40-160 mg QD) Ph. II for schizophrenia

625k-cmpd cell-based screen (21 nM hit) + opt

Journal of Medicinal Chemistry

Takeda, San Diego, US

Chemical structure of the TAK-041 Takeda GPR139 agonist

The Takeda GPR139 agonist, TAK-041, is a CNS-penetrant GPCR agonist being explored for schizophrenia symptoms and is an interesting example of a triazinone-containing clinical candidate. GPR139 is an orphan GPCR…


get free samples and a Premium trial

Premium members get access to our library of hundreds of in-depth reviews on key molecules, ten new reviews each month, novel drug approval coverage, drug discovery company updates, and more: